Fierce Pharma
OCTOBER 30, 2024
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the British drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales.
MedCity News
OCTOBER 30, 2024
After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there’s still a way forward for psychedelic medicines, experts said at HLTH. The post What’s Next for Psychedelic Medicines? appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 30, 2024
Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer’s general election. | As part of the new budget presented Wednesday by the U.K.’s Chancellor of the Exchequer, Rachel Reeves, the country is debuting a new capital grants vehicle known as the Life Sciences Innovative Manufacturing Fund.
pharmaphorum
OCTOBER 30, 2024
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for drugs in its class.Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the period used to achieve therapeutic levels in the body – is enough to lower the incidence of a potentially serious side effect known as ARIA-E, accordi
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
OCTOBER 30, 2024
Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.
pharmaphorum
OCTOBER 30, 2024
Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 30, 2024
Truth is, there are hugely positive tailwinds at our back. But the way we’ve been thinking about the problem is holding us back from solving it. Here’s why. The post Dear Mr. Buffett: Healthcare Isn’t Hopeless appeared first on MedCity News.
Fierce Pharma
OCTOBER 30, 2024
Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to distributors. | Baxter plans to exit China's IV fluids market as it faces tough local competition and as it redirects global IV supplies to the U.S. to cope with a post-hurricane shortage.
PharmaVoice
OCTOBER 30, 2024
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
Fierce Pharma
OCTOBER 30, 2024
It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug maker’s clutch of approved therapies under its fold. | In the third quarter, the company's overall sales grew 23% year over year and 8% excluding contributions from its Horizon Therapeutics buyout to $8.5 billion.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
OCTOBER 30, 2024
The UK's first female Chancellor Rachel Reeves pumps billions into NHS in the first Labour budget in 14 years
Fierce Pharma
OCTOBER 30, 2024
Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 million, falling short of consensus estimates. But behind the scenes, there was a 40% uptick in the number of new prescribers writing prescriptions for Leqembi in the third quarter versus Q2, Alicia Alaimo, Biogen’s president and head of North America, said Wednesday.
MedCity News
OCTOBER 30, 2024
The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the partners decided against further development in this indication The post Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder appeared first on MedCity News.
Fierce Pharma
OCTOBER 30, 2024
It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, Skyrizi is now on top for the Illinois pharma giant. This year, AbbVie's Humira successors are expected to bring in revenues of $17 billion.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
OCTOBER 30, 2024
A paper has a described the first reported use of nanoemulsions as a novel delivery vehicle for the oral drug bedaquline (BDQ) “with high loading efficiency as a liquid dosage form”, according to the authors. The researchers explained that in recent decades, the industry has placed significant focus on lipid-based nanocarrier formulations for oral drug delivery.
Fierce Pharma
OCTOBER 30, 2024
Several recent developments have caused many people in our industry to think differently about affordability and access. | GoodRx’s integrated platform gives pharma companies a seamless way to deliver value to consumers and HCPs at scale while navigating today’s complex healthcare system.
pharmaphorum
OCTOBER 30, 2024
The head of AstraZeneca's Chinese operations, Leon Wang, has been placed under investigation by the authorities in Beijing
Pharmaceutical Technology
OCTOBER 30, 2024
Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare conditions.
PharmaTech
OCTOBER 30, 2024
The company will be expanding its quality control testing capabilities at its San Diego, Calif. biologics development and manufacturing site.
Pharmaceutical Technology
OCTOBER 30, 2024
GlaxoSmithKline (GSK) has entered an agreement to acquire Chimagen Biosciences’ CMG1A46 for $300m upfront.
pharmaphorum
OCTOBER 30, 2024
Sales of GSK's RSV vaccine Arexvy plummet in Q3 after change to US usage advice, but Pfizer's rival Abrysvo holds up much better
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
OCTOBER 30, 2024
Green chemistry has the potential to revolutionise the pharmaceutical industry.
Pharmacy Times
OCTOBER 30, 2024
Results indicate that sublingual epinephrine can resolve symptoms, including swelling of the face and throat, associated with oral allergy syndrome in minutes.
Pharmaceutical Technology
OCTOBER 30, 2024
Barman-Aksӧzen shared her experience of guiding treatment research for her own ultra rare disorder, erythropoietic protoporphyria (EPP).
ALULA
OCTOBER 30, 2024
In an era of rapid change, the most dangerous phrase in business is, “We've always done it this way.” Yet, many leaders struggle to adapt, stuck in outdated approaches. But what if you could break free from the status quo and lead your team into a brighter, more innovative future?
PharmaTech
OCTOBER 30, 2024
In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.
PharmExec
OCTOBER 30, 2024
The trials will investigate datopotamab deruxtecan in combination with treatments including rilvegostomig, osimertinib, and chemotherapy in patients with nonsquamous non-small cell lung cancer.
Pharmaceutical Technology
OCTOBER 30, 2024
Pharmaceutical management expert Kenneth Getz shares insights on broader trends in the pharma sector influencing the recent wave of layoffs.
PharmExec
OCTOBER 30, 2024
Accelerated approval is based on results of the ASC4FIRST Phase III trial, which demonstrated Scemblix's superior efficacy in achieving major molecular response compared to standard of care tyrosine kinase inhibitors in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
300 
Let's personalize your content